Skip to main content

Christopher Bang Newgard

W. David and Sarah W. Stedman Distinguished Professor of Nutrition in the School of Medicine
Pharmacology & Cancer Biology
Duke Box 104775, Durham, NC 27710
300 North Duke Street, Durham, NC 27701

Overview


Over its 16 year history, our laboratory has investigated mechanisms of metabolic regulation and fuel homeostasis in mammalian systems. Major projects include: 1) Mechanisms involved in regulation of insulin secretion from pancreatic islet β-cells by glucose and other metabolic fuels; 2) Development of methods for protection of β-cells against immune-mediated damage; 3) Studies on spatial organization and regulation of systems controlling hepatic glucose balance; 4) Studies on the mechanisms involved in lipid-induced impairment of insulin secretion and action in diabetes.

Current Appointments & Affiliations


W. David and Sarah W. Stedman Distinguished Professor of Nutrition in the School of Medicine · 2002 - Present Pharmacology & Cancer Biology, Basic Science Departments
Professor of Pharmacology and Cancer Biology · 2002 - Present Pharmacology & Cancer Biology, Basic Science Departments
Director, Sarah W. Stedman Nutrition and Metabolism Center · 2002 - Present Sarah Stedman Nutrition & Metabolism Center, Duke Molecular Physiology Institute
Professor in Medicine · 2020 - Present Medicine, Endocrinology, Metabolism, and Nutrition, Medicine
Member of the Duke Cancer Institute · 2002 - Present Duke Cancer Institute, Institutes and Centers
Affiliate, Duke Global Health Institute · 2009 - Present Duke Global Health Institute, University Institutes and Centers

In the News


Published August 13, 2024
New Use of an Old Hormone Leads to First Drug for a Type of Liver Disease
Published November 16, 2023
Which Duke Scholars Made the Most Cited List?
Published March 28, 2023
The Case of the Mysterious $11 Million Benefactor

View All News

Recent Publications


Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF.

Journal Article JACC Basic Transl Sci · March 2025 Growing evidence supports therapeutic ketosis in heart failure with reduced ejection fraction, though uncertainty exists regarding use with SGLT2i and dose-dependent effects. In a phase I trial of 2 ketone ester (KE) doses in 20 heart failure with reduced ... Full text Link to item Cite

Integration of metabolomic and transcriptomic analyses reveals regulatory functions of the ChREBP transcription factor in energy metabolism.

Journal Article Cell Rep · February 25, 2025 The transcription factor carbohydrate response element binding protein (ChREBP) activates genes of glucose, fructose, and lipid metabolism in response to carbohydrate feeding. Integrated transcriptomic and metabolomic analyses in rats with GalNac-siRNA-med ... Full text Link to item Cite

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Journal Article Circ Heart Fail · November 2024 BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar ef ... Full text Link to item Cite
View All Publications

Recent Grants


Fibro/Adipogenic Progenitor Metabolic Reprogramming for Age-Related Muscle Fibrosis

ResearchMentor · Awarded by National Institutes of Health · 2024 - 2029

Endocrinology and Metabolism Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029

Reprogramming glutamine metabolism in pancreatic beta cells

ResearchPrincipal Investigator · Awarded by University of Pennsylvania · 2024 - 2028

View All Grants

Education, Training & Certifications


University of Texas, Dallas · 1984 Ph.D.